Understanding the impact of health insurance is critical, particularly in the era of Affordable Care Act Medicaid expansion. The electronic health record (EHR) provides new opportunities to quantify health outcomes.
ObjectiveTo assess changes in biomarkers of chronic disease among community health center (CHC) patients who gained Medicaid coverage with the Oregon Medicaid expansion (2008–2011).
DesignProspective cohort. Patients were followed for 24 months, and rate of mean biomarker change was calculated. Time to a controlled follow-up measurement was compared using Cox regression models.
Setting/PatientsUsing EHR data from OCHIN (a non-profit network of CHCs) linked to state Medicaid data, we identified three cohorts of patients with uncontrolled chronic conditions (diabetes, hypertension, and hyperlipidemia). Within these cohorts, we included patients who gained Medicaid coverage along with a propensity score-matched comparison group who remained uninsured (diabetes n = 608; hypertension n = 1244; hyperlipidemia n = 546).
Main MeasuresHemoglobin A1c (HbA1c) for the diabetes cohort, systolic and diastolic blood pressure (SBP and DBP, respectively) for the hypertension cohort, and low-density lipoprotein (LDL) for the hyperlipidemia cohort.
Key ResultsAll cohorts improved over time. Compared to matched uninsured patients, adults in the diabetes and hypertension cohorts who gained Medicaid coverage were significantly more likely to have a follow-up controlled measurement (hazard ratio [HR] =1.26, p = 0.020; HR = 1.35, p < 0.001, respectively). No significant difference was observed in the hyperlipidemia cohort (HR = 1.09, p = 0.392).
ConclusionsOCHIN patients with uncontrolled chronic conditions experienced objective health improvements over time. In two of three chronic disease cohorts, those who gained Medicaid coverage were more likely to achieve a controlled measurement than those who remained uninsured. These findings demonstrate the effective care provided by CHCs and the importance of health insurance coverage within a usual source of care setting.
Clinical Trials Registration: NCT02355132 [https://clinicaltrials.gov/ct2/show/NCT02355132]
Electronic supplementary materialThe online version of this article (doi:10.1007/s11606-017-4051-9) contains supplementary material, which is available to authorized users.
KEY WORDS: Medicaid, access to healthcare, biomarkers
INTRODUCTIONIn 2014, implementation of the Affordable Care Act (ACA) reshaped the landscape of health insurance in America. During the first 15 months, more than 13 million Americans gained coverage through federally sponsored state Medicaid expansion that increased eligibility to adults making up to 138% of the federal poverty level (FPL). Though some of these individuals had insurance previously, most were uninsured.1 With the increased access to health insurance, it is important to understand the health impacts of gaining coverage.
Community health centers (CHCs) provide healthcare for uninsured Americans as well as those with Medicaid coverage; before implementation of the ACA, CHCs provided 61 million medical care visits, over 35% of which were to uninsured patients.2 Despite lack of health insurance, many CHC patients receive care for acute and chronic conditions and preventive care.3 , 4 This care often comes at deeply discounted rates made possible by alternative funding sources.5 These clinics fill a critical need by providing high-quality care regardless of insurance status.3 , 6 – 8 Therefore, understanding whether Medicaid expansion has an additive impact on the excellent care received by CHC patients is crucial.
A large body of research emphasizes the association between access to health insurance, receipt of needed care, and improved health outcomes.9 – 13 Oregon independently expanded Medicaid to the FPL prior to implementation of the ACA, and randomly selected applicants from a pool of individuals who added their names to a reservation list.13 Studies from Oregon’s Medicaid expansion show that individuals report improvement in perceived health and less financial hardship, but the impact of Medicaid insurance on health outcomes is mixed.14 – 16 Past studies have not fully accounted for access to a usual source of primary care and have employed surrogate measures of health outcomes (i.e., an individual’s recollection of their disease control) instead of measured biomarker change.
By providing an accurate, objective report of disease biomarkers, the electronic health record (EHR) offers the opportunity for a new perspective on the health impacts of Medicaid. The EHR also allows for evaluation of an uninsured comparison group normally excluded from claims-based studies. A few studies have used the EHR to assess biomarkers of chronic disease, but use of the EHR to assess the impact of health insurance expansion on biomarker change is a novel approach. When linked to state Medicaid records, these data can provide a longitudinal perspective of the quality of healthcare and impact of Medicaid among patients with a usual source of care. Because long-term data on the effects of the ACA are only now becoming available, we must examine past Medicaid expansions to assess the potential impact of these policies.
To meet this need, we assessed changes in biomarkers of chronic disease among CHC patients with uncontrolled chronic conditions who gained new Medicaid coverage compared to a matched set of patients who remained continuously uninsured during a period of Medicaid expansion in Oregon (2008–2011). Here, we focus on cardiovascular disease, since it is the leading cause of death in the United States. Specifically, we include the following cardiovascular disease risk factors: high blood pressure, high low-density lipoprotein (LDL) cholesterol, and diabetes.17 Many cardiovascular conditions and associated morbidities are preventable with timely preventive care, yet rates of receipt of age-appropriate preventive services remain suboptimal, and inequities exist.18 – 21
METHODS Data Sources OCHIN Electronic Health Record (EHR)OCHIN, Inc. (not an acronym) is a nonprofit health information technology organization providing a centrally hosted, linked instance of the Epic® EHR to its members. EHR data are managed, validated, cleaned, and warehoused at OCHIN.22 We used OCHIN EHR data to extract demographic and encounter information, including biomarker measurements taken during clinic visits.
Medicaid Enrollment DataWe obtained Medicaid enrollment data from the state of Oregon and linked it to EHR data using unique Medicaid patient identifiers. We utilized this data set to define the cohort of patients with coverage during the study period and to identify Medicaid coverage dates.
Study PopulationPatients were required to have an initial uncontrolled biomarker result recorded in the EHR within 6 months before or after the date they gained Medicaid coverage. All participants were adult CHC patients who gained Oregon Medicaid coverage between 2008 and 2011 after being uninsured for a period of ≥6 months. Patients were included if, for the entire study period (defined below), they were aged 19–64, not pregnant, not deceased, and had no evidence of private or Medicare insurance. We followed each patient in the EHR for 24 months from his or her initial elevated biomarker reading. To examine biomarker changes over time, we included only patients with a follow-up measurement during the study period. Because some patients had no follow-up measurement during this period (11.9% for diabetes, 3.6% for hypertension, and 34.4% for hyperlipidemia cohorts), we performed a sensitivity analysis of the “full population,” including those without a follow-up measurement (see online Appendix).
We used propensity score methodology to match insured patients to a comparison group who met the same inclusion criteria but were continuously uninsured throughout the 24-month study period. Propensity score models included baseline variables for demographics (e.g., age, race/ethnicity, federal poverty level, baseline biomarker result, disease-specific medication prescription in the pre-period), insurance history, CHC utilization (e.g., number of encounters in pre-period, number of biomarker measurements in the pre-period), co-morbidities (e.g., number of chronic conditions), and health center characteristics based on the Aday and Andersen behavioral model of health services utilization23 and prior studies.16 , 24 Within each chronic condition cohort, we completed a one-to-one nearest-neighbor match on propensity scores within a caliper restriction. The final cohorts included three matched chronic condition cohorts: diabetes = 608 (304 matched pairs); hypertension = 1244 (622 matched pairs); hyperlipidemia = 564 (273 matched pairs). See online Appendix for additional detail on propensity score matching.
Outcome MeasuresThe biomarker outcomes of interest were hemoglobin A1c (HbA1c) for the diabetes cohort, systolic and diastolic blood pressure (SBP and DBP, respectively) for the hypertension cohort, and LDL for the hyperlipidemia cohort. Threshold values to identify each cohort were based on national consensus guidelines25 – 28 and previous studies.12 , 29 , 30 Disease was considered “uncontrolled” (regardless of treatment status) for diabetes, hyperlipidemia, and hypertension cohorts, respectively, if HbA1c ≥9%, LDL ≥160 mg/ml, or at least two elevated blood pressure measurements with either SBP ≥150 mmHg or DBP ≥100 mmHg. If patients met criteria for multiple cohorts, they were included in all cohorts for which they qualified.
To generate hypotheses regarding the nature of observed differences, we also examined prescription orders of disease-specific medication for each cohort—hypoglycemic drugs for the diabetes cohort, antihypertensive drugs for the hypertension cohort, and antihyperlipidemic drugs for the hyperlipidemia cohort. Appropriate medications were identified within the EHR based on pharmaceutical class, and medication lists were reviewed and agreed upon by two physician researchers.
AnalysesWe examined differences in baseline characteristics between the insured and uninsured patients, tested using standardized differences, chi-square, and t tests. We performed three analyses for each biomarker: (1) time-to-event analysis assessing time from uncontrolled baseline measurement to a follow-up controlled measurement; (2) longitudinal analysis modeling the mean biomarker value over time; and (3) logistic regression analysis to estimate the odds of having a disease-specific medication ordered during the study period.
Time to a controlled follow-up measurement (i.e., event) was defined as the time from baseline elevated measurement to an HbA1c measurement <9% for the diabetes cohort, an LDL measurement <160 mg/dL for the hyperlipidemia cohort, and a blood pressure measurement with both SBP < 150 mmHg and DBP < 100 mmHg for the hypertension cohort. To examine the relationship between insurance status and time from an elevated to a controlled measurement, Kaplan–Meier survival curves were plotted, and a Cox proportional hazards model was used to analyze differences in time to controlled measurement by insurance status. Hazard ratios (HRs) were calculated and a robust sandwich variance estimator was used to construct 95% confidence intervals (CIs) of HRs to account for correlation of subjects within propensity score-matched sets and subjects nested in CHCs.31
For the longitudinal analysis, we modeled the mean biomarker over time for insured and uninsured patients. We descriptively produced individual and mean longitudinal profile plots of biomarker measurements by insurance status for each follow-up cohort. Visual examination of the plots showed non-linear patterns of change over time, so we modeled change separately from 0 to 6 months and 6 to 24 months using linear mixed effect models to model the mean biomarkers while accounting for multiple levels of clustering (temporal correlation within individuals, matched pairs, and patients within CHCs). Final models were tested for fit, and included independent variables for insurance status, time, “spline” (slope change at 6 months) interactions between time and insurance and the spline and insurance, and covariates with residual imbalance after propensity score matching (see online Appendix). Identical models were used for the sensitivity analyses of the “full population” including those without a follow-up biomarker measurement (see online Appendix).
Adjusted mean values from the final model across three time points (0, 6, and 24 months) were calculated for both the insured and uninsured groups, and CIs were calculated using a clustered bootstrap procedure (5000 repeats).32 Rates of change from baseline to 6 months and from 6 to 24 months were generated, and differences in the rates of mean biomarker change between insured and uninsured groups were tested. Lastly, we assessed between-group differences in whether any disease-specific prescription medications were ordered at any point during the follow-up period, using a generalized estimating equation (GEE) logistic regression model, controlling for covariates with residual imbalance in propensity score models and accounting for clustering of matched patients and patients within clinics.
Analyses were conducted using R version 3.2.1 and SAS version 9.4 software (SAS Institute Inc., Cary, NC). All statistical tests were two-sided, and significance was defined as a p value <0.05. The study was approved by the Oregon Health & Science University Institutional Review Board.
RESULTSConsistent with overall OCHIN health information network demographics, the majority in each chronic disease cohort had household income below the FPL (>75%) and resided in urban areas (>85%). A large percentage of patients had been previously insured by Medicaid (>80%) and had more than five visits to an OCHIN clinic prior to the study (>50%).
Prior to propensity score matching, all chronic disease cohorts showed significant differences between newly insured and uninsured patients across multiple baseline patient and clinic characteristics. After propensity score matching, cohorts showed improvement in the balance of baseline characteristics between insured and uninsured groups, with only two characteristics showing a difference of >0.1 standard deviation (SD) between groups (race/ethnicity in the hyperlipidemia cohort/number of pre-baseline encounters for all three cohorts; Table 1). Characteristics showing a difference of >0.1 SD were included as categorical covariates in final models.
Table 1.Baseline Characteristics of Matched Cohorts
Diabetes cohort Hypertension cohort Hyperlipidemia cohort 304 matched pairs 622 matched pairs 273 matched pairs N = 608 from 42 CHCs N = 1244 from 59 CHCs N = 546 from 44 CHCs Insured Uninsured Std. difference Insured Uninsured Std. difference Insured Uninsured Std. difference Gender, % −0.079 −0.006 −0.030 Male 52.0 48.0 51.8 51.5 42.9 41.4 Age at baseline (years), % 0.024 19–39 23.0 22.0 18.8 19.3 0.013 17.2 16.1 0.033 40–49 32.2 32.6 33.0 33.0 30.8 31.9 50–63 44.7 45.4 48.2 47.8 52.0 52.0 Race/ethnicity, % 0.092 0.036 0.130* Hispanic 26.6 30.6 9.7 10.3 16.9 18.7 Non-Hispanic white 55.3 53.0 72.3 72.2 66.7 69.2 Non-Hispanic other 16.8 15.5 15.8 15.0 14.3 10.3 Missing/unknown 1.3 1.0 2.3 2.6 2.2 1.8 Language, % 0.087 0.092 0.059 Spanish 20.1 23.4 5.6 5.8 12.5 14.3 English 74.0 71.7 86.7 88.8 79.9 78.8 Other 5.9 4.9 6.8 4.7 7.0 6.2 Missing/unknown 0 0 1.0 0.8 0.7 0.7 Federal poverty level (FPL), % 0.089 0.037 0.083 ≤ 100% FPL 85.2 81.9 84.4 83.8 81.0 77.7 > 100% FPL 13.2 16.1 13.8 14.8 18.0 21.3 Missing/unknown 1.6 2.0 1.8 1.5 1.1 1.1 Urban/rural, % 0.054 0.053 0.053 Urban 93.4 92.8 89.9 88.3 87.2 88.6 Rural 5.6 6.6 9.7 11.3 11.7 10.6 Missing/unknown 1.0 0.7 0.5 0.5 1.1 0.7 Had prior Medicaid insurance, % 86.2 84.9 0.037 86.7 86.0 0.019 85.0 82.4 0.070 No. of pre-baseline encounters, % Mean (SD) 16.7 (23.0) 16.6 (18.9) 0.005 16.2 (20.2) 19.5 (25.7) −0.145* 12.8 (21.5) 15.4 (17.2) −0.132* 0 7.6 6.9 0.312* 0 0 0.130* 4.0 2.6 0.294* 1–2 27.6 15.8 20.1 16.2 26.7 21.3 3–5 9.2 12.5 17.9 15.9 20.9 15.0 6–10 10.2 14.5 16.2 16.4 15.4 14.7 > 10 45.4 50.3 45.8 51.5 33.0 46.5 No. of uncontrolled biomarker measurements pre-baseline†, % 0 75.3 73.0 0.063 24.0 22.4 0.053 92.3 91.2 0.065 1 11.5 13.5 15.1 14.2 5.5 7.0 ≥ 2 13.2 13.5 60.9 63.5 2.2 1.8 Chronic multi-morbidity‡, % 53.6 55.6 −0.040 36.2 35.1 0.024 31.1 33.0 −0.039Kaplan–Meier survival curves and corresponding log-rank survival tests showed significantly different survival functions between the insured and uninsured groups in time to achieve a controlled measurement among the diabetes and hypertension cohorts but not the hyperlipidemia cohort (Fig. 1). Among the diabetes and hypertension cohorts, patients who gained Medicaid insurance were significantly more likely to achieve a controlled measurement than those who remained continuously uninsured (diabetes: [HR] = 1.26, p = 0.020; hypertension: HR = 1.35, p < 0.001; in the hyperlipidemia cohort, this trend was not statistically significant [HR = 1.09, p = 0.392]).
Figure 1.Kaplan-Meier survival curves: time from baseline elevated measurement to a controlled measurement by insurance category among propensity score-matched patients. HR hazard ratio, CI confidence interval. Note: Cox regression modeling was used to estimate HRs, with p values noted on each figure. Models were adjusted for covariates with residual imbalance (SD ≥ 0.10). A robust sandwich variance estimator was used to account for correlation of subjects within propensity score-matched sets and subjects nested in community health centers.
All biomarkers improved rapidly during the first 6 months after the elevated baseline measurement, then more slowly during months 6 through 24. This trend of changing rates at 6 months was accounted for in our longitudinal models of biomarkers. For all three chronic disease cohorts, the average biomarker measurements, as represented by locally weighted scatterplot smoothing (LOWESS) curves, were consistently (and increasingly) lower for the group that gained Medicaid insurance compared to the continuously uninsured, though statistical differences in rates of improvement were observed only during the first 6 months among the diabetes cohort (–0.34%/month compared to –0.26%/month, p = 0.02; Fig. 2, Table 2).
Figure 2.Patient-specific profile plots and average LOWESS curves: biomarkers over time by insurance category among propensity score-matched patients. Note: Black lines denote limits of “controlled” range. LOWESS curves are denoted by solid lines, and represent a locally weighted average of biomarkers over time, stratified by insurance status. Thin dashed lines represent patient-specific profile plots. Due to large sample sizes, the points in the two hypertension cohort graphs represent 100 matched pairs selected at random, whereas the LOWESS curves reflect results from the entire hypertension cohort.
Table 2.Mean Biomarker Levels and Difference in Mean Biomarker Rates at Baseline, 6 Months, and 24 Months by Insurance Status
Outcome Mean biomarker levels and 95% CI Rates of change (units/month) Baseline 6 months 24 months 0 to 6 months p value 6 to 24 months p value HbA1c (%) (n = 608) Insured 10.6 (10.4, 10.7) 9.0 (8.8, 9.3) 9.4 (9.2, 9.7) −0.34 0.021 0.03 0.304 Uninsured 10.6 (10.5, 10.7) 9.1 (8.8, 9.3) 9.4 (9.3, 9.7) −0.26 0.02 SBP (mmHg) (n = 1244) Insured 147.8 (146.9, 149.0) 134.8 (133.6, 135.7) 135.4 (134.3, 136.9) −2.18 0.377 0.04 0.965 Uninsured 149.1 (148.0, 150.3) 136.8 (135.7, 138.0) 137.5 (136.2, 139.0) −2.04 0.03 DBP (mmHg) (n = 1244) Insured 94.1 (93.6, 94.9) 84.6 (84.1, 85.5) 84.4 (83.4, 85.5) −1.57 0.248 −0.01 0.329 Uninsured 94.7 (94.1, 95.5) 86.0 (85.4, 86.9) 85.1 (84.1, 86.1) −1.45 −0.05 LDL (mg/dL) (n = 546) Insured 181.3 (180.4, 185.2) 131.0 (122.3, 134.9) 148.5 (142.3, 158.5) −8.37 0.445 0.97 0.150 Uninsured 181.5 (179.0, 185.2) 135.5 (125.3, 137.8) 141.3 (138.7, 152.7) −7.78 0.32A large percentage of the total patients were likely to receive an order for prescription medication for their uncontrolled chronic condition during the study period (>99% in diabetes cohort, >85% in hypertension cohort, and >75% in hyperlipidemia cohort). Among all three cohorts, a slightly larger proportion of patients who gained Medicaid received a prescription for medication compared to those who remained uninsured; however, this difference was significant only for the hyperlipidemia cohort (85.4% vs. 78.4%, p < 0.01; Table 3).
Table 3.Proportion of Patients with Disease-Specific Medication Ordered During the Study Period
Cohort Proportion with medication prescribed OR 95% CI p value* Diabetes 0.657 Insured 99.3% 1.51 (0.25, 9.14) Uninsured 99.1% Hypertension 0.075 Insured 90.8% 1.41 (0.97, 2.06) Uninsured 87.3% Hyperlipidemia 0.016 Insured 85.4% 1.68 (1.10, 2.58) Uninsured 78.4% DISCUSSIONThis study produced three principal findings among CHC patients with an uncontrolled chronic condition: (1) both insured and uninsured patients experienced improvement in biomarkers over time; (2) in two of the three cohorts, patients who gained Medicaid coverage were more likely to achieve control within the study period; and (3) most patients received prescriptions for disease-specific medications regardless of insurance status.
These findings are consistent with a large body of literature demonstrating the importance of both health insurance and a consistent usual source of care in achieving better health.4 , 33 – 38 They also support previous studies demonstrating the excellent quality of care provided by CHCs.3 , 6 – 8 These findings surpass those of prior studies, as they reflect an objective quantification of longitudinal health outcomes and the inclusion of an uninsured comparison group.
Our findings demonstrate the impact of new access to Medicaid on the health of CHC patients. Gaining coverage was associated with improved biomarkers for this group of patients already benefiting from a consistent usual source of care, suggesting that expansions in Medicaid coverage will likely be associated with improvements in the health of other uninsured populations. Future analyses could assess the long-term clinical and economic impacts of this health improvement.
Surprisingly, though patients in the diabetes and hypertension cohorts who gained Medicaid were more likely to achieve a controlled biomarker measurement than those who were uninsured, we did not identify significant differences in prescription rates for disease-specific medications. Patients in the hyperlipidemia cohort who gained Medicaid insurance were no more likely to achieve a controlled measurement than uninsured patients, but they were more likely to have a prescription ordered for lipid-lowering medication. This result is likely attributable to the lower rate of follow-up for this cohort, as these differences were not observed in a sensitivity analysis of the full population (see online Appendix). The comparable rates of prescribing suggest that clinicians’ prescribing patterns are similar regardless of insurance status. It is possible that uninsured patients filled prescriptions less frequently or experienced delays due to an inability to afford medications; pharmacy data on dispensed prescriptions were not available to confirm this theory. It is also possible that between-group differences in unmeasured medical or social factors (e.g., health literacy, patient engagement) played a role in biomarker improvement. Though these factors were not measurable with our data, future studies could expand population descriptors to explore the additional complex social and clinical factors that may affect care.
This study provokes many questions in the context of the ACA. With early studies showing increased utilization of healthcare at CHCs,39 – 41 maintaining access with growing patient panels will be essential to providing timely care to patients with chronic diseases.42 This may have both workforce and workflow implications, and may call for innovations to our healthcare delivery system.
LimitationsThe clinical impact of small absolute differences in biomarker changes is uncertain, though there may be population impacts of a more broadly insured patient population at CHCs not captured in this study.43 For example, a greater number of insured patient visits may facilitate additional resources for and implementation of other activities such as behavioral health counseling or more ambitious clinic-wide quality improvement efforts that may improve patients’ health outcomes. Therefore, it is possible that unmeasured services provided to all patients contributed to the observed improvements in biomarkers in both the insured and uninsured groups. Our main analytic method was analogous to a per-protocol approach used in randomized controlled trials, where we analyzed data from subjects who did not deviate from the protocol (i.e,. gained Medicaid or were continuously uninsured). This approach could have introduced bias. Future studies could apply an intent-to-treat approach with a broader comparison group of patients who were uninsured and/or gained some insurance in the follow-up period. Propensity score methods allowed us to control for an extensive list of baseline covariates, including FPL and comorbidities that influence Medicaid eligibility, but unmeasured confounding may still exist. One likely scenario is self-selection into Medicaid among certain individuals with unmeasured health events occurring between baseline and follow-up; if patients with worse health status self-selected into Medicaid, this would create a bias toward the null with regard to the outcomes investigated here.
Although the direct health metrics available through the EHR represent a novel means of capturing improvements in health outcomes (arguably, a new gold standard), using the EHR in this study limited our perspective to patients who visited a CHC. Thus, we cannot report on the health of those who did not (or could not) access CHC care. Since lack of insurance is a known barrier to accessing healthcare,11 , 44 the uninsured comparison group in this study is not representative of all uninsured patients. Though it is possible patients received additional care outside our network, prior studies suggest that patients continue to utilize CHC care after gaining health insurance rather than transitioning care elsewhere.40 , 45 – 49 Our findings are not generalizable to other health outcomes, other chronic diseases, or other health systems. Due to the relatively recent implementation of EHRs from which to capture data, we were unable to assess the impact of Medicaid on long-term health outcomes such as mortality. Additionally, given the study period (2008–2011), we were unable to produce pre-period biomarker trends to judge whether they looked similar between insurance groups. Future research should consider evaluating the parallel trends assumption in biomarker levels when assessing the impact of gaining Medicaid coverage on health outcomes.
Assessment of continuity of insurance status was beyond the scope of this study. It is possible that some individuals who were classified as “gained new Medicaid” actually lost coverage after their first coverage window of 6 months. Churning on and off Medicaid coverage is common among CHC patients50 and has been associated with poor health outcomes.4 , 51 – 53 Any heterogeneity in insurance status could have diluted an underlying effect.
As with any natural policy experiment, the results of this study reflect observational study design enabling timely, “real-world” analysis; this study design is subject to unmeasured confounding and bias. Results may not generalize to other populations or Medicaid expansions. While this study provides insight into the outcome of a pre-ACA Oregon Medicaid expansion, it cannot predict more widespread outcomes in the setting of the ACA. More research is urgently needed to examine the impacts of these new policies.
CONCLUSIONSNew enrollment in Medicaid during a period of Medicaid expansion in Oregon was associated with improved health outcomes among cohorts of CHC patients with uncontrolled diabetes and hypertension. These findings argue for Medicaid expansion and continued support for CHCs, and continued assessment of the complex relationships between insurance, access to a usual source of care, and health outcomes. The EHR provides a novel lens through which to examine health policies, particularly those impacting vulnerable populations.
Electronic supplementary materialBelow is the link to the electronic supplementary material.
FundingThis project was funded in part by the National Institutes of Health/National Heart, Lung, and Blood Institute, R01HL107647, and the Agency for Healthcare Research and Quality, R01HS024270.
Prior PresentationsThese results were presented at the 43rd North American Primary Care Research Group Annual Meeting, October 24–28, 2015, in Cancun, Mexico.
Conflict of InterestThe authors declare that they do not have a conflict of interest.
ReferencesThis section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary MaterialsRetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3
